Immune therapy for cancer.

Over the past decade, immune therapy has become a standard treatment for a variety of cancers. Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-established cancer therapies. Immune modulation is a principal element of supportive care for many high-dose chemotherapy regimens. In addition, immune activation is now appreciated as central to the therapeutic mechanism of bone marrow transplantation for hematologic malignancies. Advances in our understanding of the molecular interactions between tumors and the immune system have led to many novel investigational therapies and continue to inform efforts for devising more potent therapeutics. Novel approaches to immune-based cancer treatment strive to augment antitumor immune responses by expanding tumor-reactive T cells, providing exogenous immune-activating stimuli, and antagonizing regulatory pathways that induce immune tolerance. The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments.

[1]  P. Khaw,et al.  A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. , 2007, Ophthalmology.

[2]  M. Girardi,et al.  Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[4]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Chi‐Huey Wong,et al.  Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids , 2007, Proceedings of the National Academy of Sciences.

[6]  R. Medzhitov,et al.  Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88 , 2007, Science.

[7]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Iida,et al.  Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. , 2007, Molecular immunology.

[9]  M. Gillison,et al.  Clinical implications of human papillomavirus in head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[11]  A. Enk,et al.  Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro , 2007, International journal of cancer.

[12]  Yoichiro Iwakura,et al.  Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. , 2007, Cancer research.

[13]  D. Carrasco,et al.  MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. , 2007, The Journal of clinical investigation.

[14]  A. Enk,et al.  Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. , 2005, Cancer research.

[15]  D. Lynch The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer , 2008, Immunological reviews.

[16]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[17]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[18]  C. Gregory,et al.  Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt’s Lymphoma1 , 2005, The Journal of Immunology.

[19]  J. Byrd,et al.  Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[22]  Antonio Lanzavecchia,et al.  Regulation of Dendritic Cell Migration to the Draining Lymph Node , 2003, The Journal of experimental medicine.

[23]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[24]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[25]  A. Enk,et al.  RAGE signaling sustains inflammation and promotes tumor development , 2008, The Journal of experimental medicine.

[26]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[27]  Alexander Tsertsvadze,et al.  The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force , 2007, Annals of Internal Medicine.

[28]  S. Gasser,et al.  The DNA damage response arouses the immune system. , 2006, Cancer research.

[29]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[30]  T. Iizasa,et al.  A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[31]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[32]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[33]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[34]  M. Stoler,et al.  The Distribution of Low and High-risk HPV Types in Vulvar and Vaginal Intraepithelial Neoplasia (VIN and VaIN) , 2006, The American journal of surgical pathology.

[35]  K. Sugamura,et al.  Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 , 2004, Nature Reviews Immunology.

[36]  Larry L. Green,et al.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.

[37]  Richard Pazdur,et al.  FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.

[38]  J. Meyerhardt,et al.  Systemic therapy for colorectal cancer. , 2005, The New England journal of medicine.

[39]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[40]  G. Giaccone,et al.  The immunoregulatory role of CD1d-restricted natural killer T cells in disease. , 2004, Clinical immunology.

[41]  S. Glaser,et al.  Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. , 2000, Critical reviews in oncology/hematology.

[42]  R. Schilsky,et al.  High-dose methotrexate: a critical reappraisal. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[44]  S. Itzkowitz,et al.  Cancer in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[45]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[46]  R. Berger,et al.  Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies , 2008, Clinical Cancer Research.

[47]  M. Smyth,et al.  NKT cells - conductors of tumor immunity? , 2002, Current opinion in immunology.

[48]  G. Zimet,et al.  Appropriate use of cervical cancer vaccine. , 2008, Annual review of medicine.

[49]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[50]  G. Fleuren,et al.  Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model , 2004, Cancer Research.

[51]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[52]  M. Zand,et al.  CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. , 2007, Blood.

[53]  Steven A. Rosenberg,et al.  Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients , 2003, Journal of immunotherapy.

[54]  Erik Hooijberg,et al.  Immortalization of Human CD8+ T Cell Clones by Ectopic Expression of Telomerase Reverse Transcriptase1 , 2000, The Journal of Immunology.

[55]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[56]  A. Eggermont,et al.  Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs , 2005, Annals of Surgical Oncology.

[57]  L. Golitz,et al.  Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. , 2004, Journal of the American Academy of Dermatology.

[58]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[59]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[60]  M. V. D. van den Brink,et al.  Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity1 , 2006, The Journal of Immunology.

[61]  T. Molina,et al.  T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. , 2001, Gastroenterology.

[62]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[63]  S. Groshen,et al.  FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[65]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[66]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[67]  John Powell,et al.  Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. , 2007, Arthritis and rheumatism.

[68]  H. Fiegl,et al.  The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.

[69]  S. Adams,et al.  Manipulating dendritic cell biology for the active immunotherapy of cancer. , 2004, Blood.

[70]  W. Sterry,et al.  Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma , 2008, Journal of immunotherapy.

[71]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[72]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[73]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  R. Steinman,et al.  The use of dendritic cells in cancer immunotherapy. , 2003, Current opinion in immunology.

[75]  K. Boyd,et al.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function , 2007, Nature.

[76]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[77]  J. Terdiman,et al.  Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies , 2005, The American Journal of Gastroenterology.

[78]  R H Wheeler,et al.  Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  W. Heindel,et al.  FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[81]  C. Macleod,et al.  Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[82]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  T. Braun,et al.  Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[85]  G. Dranoff,et al.  Capitalizing on the Immunogenicity of Dying Tumor Cells , 2008, Clinical Cancer Research.

[86]  Y. Okamoto,et al.  Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer , 2008, Cancer Immunology, Immunotherapy.

[87]  H. Hsu,et al.  Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. , 2000, JAMA.

[88]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[91]  Andrew N. Gray,et al.  Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. , 2008, Cancer research.

[92]  L Edler,et al.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[94]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[95]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[96]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[97]  S. H. van der Burg,et al.  Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. , 2005, Vaccine.

[98]  P. Keegan,et al.  FDA drug approval summary: panitumumab (Vectibix). , 2007, The oncologist.

[99]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[100]  A. Rimm,et al.  Identical-Twin Bone Marrow Transplants for Leukemia , 1994, Annals of Internal Medicine.

[101]  Laurentiu M. Pop,et al.  The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. , 2005, International immunopharmacology.

[102]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[104]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[105]  G. Eslick Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence. , 2006, World journal of gastroenterology.

[106]  S. Derry,et al.  Imiquimod for actinic keratosis: systematic review and meta-analysis. , 2006, The Journal of investigative dermatology.

[107]  D. Alarcón-Segovia,et al.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[108]  N. Aaronson,et al.  Treatment of vulvar intraepithelial neoplasia with topical imiquimod. , 2008, The New England journal of medicine.

[109]  A. Korman,et al.  Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. , 2007, International immunology.

[110]  C. Bokemeyer,et al.  Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.

[111]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[112]  C. Drake,et al.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. , 2006, Blood.

[113]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[114]  D. Lejeune,et al.  GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. , 2007, Vaccine.

[115]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[116]  A. Hagenbeek,et al.  The therapeutic use of rituximab in non-Hodgkin's lymphoma. , 2007, European journal of haematology. Supplementum.

[117]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[118]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[119]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[120]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[121]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[123]  N. Munshi,et al.  Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. , 2004, Cancer research.

[124]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[125]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[126]  A. Böhle,et al.  Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. , 2003, The Journal of urology.

[127]  D. Kufe,et al.  Dendritic cell fusion vaccines for cancer immunotherapy , 2005, Expert opinion on biological therapy.

[128]  R. DuBois,et al.  Cyclooxygenase-2: a therapeutic target. , 2002, Annual review of medicine.

[129]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  Mitsuhiro Osame,et al.  Cellular immune response to HTLV-1 , 2005, Oncogene.

[131]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[132]  J. Wolchok,et al.  Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. , 2006, Cancer research.

[133]  J. Leonard,et al.  Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma , 2007, Clinical Cancer Research.

[134]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[135]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.

[137]  C. Davis,et al.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. , 1999, Cancer research.

[138]  C. A. de la Motte,et al.  The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. , 2007, Immunity.

[139]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[140]  C. Sousa,et al.  Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function , 2005, Nature Immunology.

[141]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[142]  J. P. Davis Experience with hepatitis A and B vaccines. , 2005, The American journal of medicine.

[143]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[144]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[145]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  V. Engelhard,et al.  Immunity to melanoma antigens: from self-tolerance to immunotherapy. , 2006, Advances in immunology.

[147]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  E. Gilboa,et al.  Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation 1 , 2003, The Journal of Immunology.

[149]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  Y. Okamoto,et al.  A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[152]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  A. Eggermont,et al.  Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcoma , 2006 .

[154]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[155]  M. Dhodapkar,et al.  Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.

[156]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[157]  R. Levy,et al.  Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  N. Tsurushita,et al.  An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.

[159]  F. Cavalli,et al.  Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue , 1995, Annals of Internal Medicine.

[160]  A. Mackensen,et al.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  W. Fair,et al.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  C. Hudis Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[163]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[164]  S. Piantadosi,et al.  Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer , 2006, Clinical Cancer Research.

[165]  S. O’Day,et al.  Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) , 2007, Cancer.

[166]  Thomas Ruzicka,et al.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. , 2002, The Lancet. Infectious diseases.

[167]  S. Wagner,et al.  Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[169]  G. Giaccone,et al.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[170]  Y. Koezuka,et al.  KRN7000, a novel immunomodulator, and its antitumor activities. , 1995, Oncology research.

[171]  Catherine J. Wu,et al.  Induction of tumor immunity following allogeneic stem cell transplantation. , 2006, Advances in immunology.

[172]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[173]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[174]  A. Dachman,et al.  Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[176]  P. Nathan,et al.  Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection , 2007, Annals of Internal Medicine.

[177]  S. Akira,et al.  Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[178]  G. Forni,et al.  Prophylactic cancer vaccines. , 2002, Current opinion in immunology.

[179]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[180]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[182]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[183]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  L. Gianni,et al.  Targeting TRAIL Agonistic Receptors for Cancer Therapy , 2007, Clinical Cancer Research.

[185]  J. Witjes,et al.  Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. , 2005, The Journal of urology.

[186]  D. Moher,et al.  Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force , 2007, Annals of Internal Medicine.

[187]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[188]  T. Juji,et al.  Therapeutic activation of Vα24^+Vβ11^+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity , 2004 .

[189]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[190]  D. Neuberg,et al.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.

[191]  R. Steinman,et al.  The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.

[192]  E. Zintzaras,et al.  The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.

[193]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[194]  Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients , 2005, The Journal of experimental medicine.

[195]  T. Iwama,et al.  A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[196]  Lars E. French,et al.  The TRAIL to selective tumor death , 1999, Nature Medicine.

[197]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[198]  N. Berinstein Enhancing cancer vaccines with immunomodulators. , 2007, Vaccine.

[199]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[201]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[202]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[203]  Hardev Pandha,et al.  Delayed Disease Progression after Allogeneic Cell Vaccination in Hormone-Resistant Prostate Cancer and Correlation with Immunologic Variables , 2005, Clinical Cancer Research.

[204]  M. Smyth,et al.  Cancer vaccines for established cancer: how to make them better? , 2008, Immunological reviews.

[205]  D. Petrylak,et al.  Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.

[206]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[207]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[208]  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer immunology, immunotherapy : CII.

[209]  Mark M. Davis,et al.  Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.

[210]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[211]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[212]  J. Blattman,et al.  Restoration of CD28 Expression in CD28− CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production , 2003, The Journal of experimental medicine.

[213]  N. Robert,et al.  A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. , 1998, Cancer investigation.

[214]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[216]  S. Leung,et al.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. , 2004, JAMA.

[217]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[218]  G. Heller,et al.  The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. , 1996, Blood.

[219]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[220]  Y. Tokura,et al.  Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity , 2001, Immunology.

[221]  T. Noda,et al.  Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. , 2004, The Journal of clinical investigation.

[222]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[223]  N. Miyamoto,et al.  Age‐ and sex‐specific cumulative rate and risk of ATLL for HTLV‐I carriers , 1989, International journal of cancer.

[224]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[225]  J. Vose,et al.  Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[227]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[228]  S. Hirohashi,et al.  FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis , 2007, Clinical Cancer Research.

[229]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[230]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.

[231]  F. Hodi,et al.  Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines , 2008, Immunological reviews.

[232]  P. Keegan,et al.  FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. , 2007, The oncologist.

[233]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[234]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[235]  G. Boulianne,et al.  Production of functional chimaeric mouse/human antibody , 1984, Nature.

[236]  S. Hernández-Díaz,et al.  Nonsteroidal anti‐inflammatory drugs and risk of lung cancer , 2007, International journal of cancer.